Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).

8565Background: We conducted a phase II trial (NCT02399371) of P in previously treated MM to characterize activity in a non-selected population and determine a PD-L1 expression threshold Methods: E...